Literature DB >> 19410321

EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy.

George V Papatheodoridis, Spilios Manolakopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19410321     DOI： 10.1016/j.jhep.2009.02.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  11 in total

1.  Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine.

Authors:  Ming Wang; Leyong Yuan; Bin Qiao; Yan Li
Journal:  Virus Genes       Date:  2013-11-08       Impact factor: 2.332

2.  Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.

Authors:  Jeong-Hoon Lee; Yuri Cho; Dong Hyeon Lee; Minjong Lee; Jeong-ju Yoo; Won-mook Choi; Young Youn Cho; Yun Bin Lee; Su Jong Yu; Jung-Hwan Yoon; Hyo-Suk Lee; Yoon Jun Kim
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

3.  Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.

Authors:  Ya-Wen Yang; Chih-Yuan Lee; Rey-Heng Hu; Po-Huang Lee; Meng-Kun Tsai
Journal:  Clin Exp Nephrol       Date:  2013-04-19       Impact factor: 2.801

4.  CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis.

Authors:  Haijun Huang; Tiangang Wu; Jian Mao; Yongxing Fang; Jiajie Zhang; Lihua Wu; Shu Zheng; Biaoyang Lin; Hongying Pan
Journal:  OMICS       Date:  2015-06

5.  RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo.

Authors:  Ya-Li Zhang; Tong Cheng; Yi-Jun Cai; Quan Yuan; Che Liu; Tao Zhang; De-Zhen Xia; Rui-Yin Li; Lian-Wei Yang; Ying-Bin Wang; Anthony E T Yeo; James Wai-Kuo Shih; Jun Zhang; Ning-Shao Xia
Journal:  BMC Microbiol       Date:  2010-08-10       Impact factor: 3.605

6.  Protective role of α2HS-glycoprotein in HBV-associated liver failure.

Authors:  Xia-Hong Dai; Pan Zhang; Mei-Fang Xiao; Rong-Rong Zhou; Bao-Xin Zhang; Guan-Sheng Hu; Ze-Bing Huang; Xue-Gong Fan
Journal:  Int J Mol Sci       Date:  2011-06-10       Impact factor: 5.923

7.  The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine.

Authors:  Jie Yan; Wen Xie; Qi Wang; Yue Li; Xing Feng; Jun Cheng
Journal:  Hepat Mon       Date:  2011-05       Impact factor: 0.660

8.  Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B.

Authors:  Bin Xu; Ning-Ming Zhou; Wei-Tian Cao; Xiao-Jing Li
Journal:  World J Gastroenterol       Date:  2018-10-07       Impact factor: 5.742

9.  Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.

Authors:  Guohong Ge; Shixia Wang; Yaping Han; Chunhua Zhang; Shan Lu; Zuhu Huang
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

Review 10.  The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis.

Authors:  Min Deng; Xin Zhou; Sheng Gao; Shi-Gui Yang; Bing Wang; Hua-Zhong Chen; Bing Ruan
Journal:  Virol J       Date:  2012-09-04       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.